Alzheimer’s Disease is one of the most devastating diseases worldwide. According to the Alzheimer’s Association, an estimated 6 million Americans are currently living with the disease, and this number is expected to triple by 2050. Fortunately, there is some good news that brings hope to those affected by this debilitating condition. Eli Lilly and Company, a global pharmaceutical company, has recently released promising Phase 3 clinical trial data on their Alzheimer’s treatment drug, donanemab. This breakthrough therapy has shown positive results in slowing down the progression of Alzheimer’s Disease, and today 4 Seasons Home Care will explore what this means for Alzheimer’s care patients and their families.
How Does This Treatment Help Alzheimer’s Victims?
Donanemab, a monoclonal antibody, removing plaque buildups in the brain known as amyloid that are a hallmark of Alzheimer’s disease. The Phase 3 clinical trial data showed that Patients who received donanemab demonstrated a 35% slower decline in memory and games, thinking, and their ability to perform daily activities, according to clinical trial data from its maker, Eli Lilly.
However, there were some side effects reported; there were three deaths in the trial among people taking the drug, two of which were attributed to adverse events such as brain swelling or microhemorrhages, known as amyloid-related imaging abnormalities or ARIA. The safety profile for this possible treatment will require thorough study and review. The trial was run in more than 1,700 patients for 18 months.
What happens next for Alzheimer’s patients?
Eli Lilly’s Phase 3 clinical trial data has been promising, and donanemab is poised to become a potential game-changer in the field of Alzheimer’s research. However, it’s important to note that this treatment for Alzheimer’s is not yet approved by the Food and Drug Administration (FDA) in the United States. Eli Lilly has indicated it plans to seek review for this treatment soon.
Hope for slowing down Alzheimer’s
Alzheimer’s Disease is a debilitating and heartbreaking disease, and the thought of slowing down its progression brings hope to many families affected by it. The promising Phase 3 clinical trial data released by Eli Lilly on their Alzheimer’s treatment donanemab has brought a new ray of hope that this illness can be managed. The potential success of donanemab should encourage us all that the investment into Alzheimer’s research can bring positive results.
Alzheimer’s will continue to be a formidable challenge, but for now, we can take solace in knowing that breakthroughs like donanemab could improve the quality of life for millions of people that are at risk or are suffering from the disease. We hope that the future holds successful safety and efficacy outcomes for this promising treatment such that it can soon be available to the general public. We are closer than ever to winning the fight against Alzheimer’s, thanks to the visionary scientists like those at Eli Lilly who have dedicated their careers to finding viable treatments.